Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC36 + ASC37
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
ASC36 + ASC37 is a peptide combination therapy being developed by Ascletis Pharmaceuticals for the treatment of obesity, diabetes, and other metabolic diseases. The combination consists of two distinct peptide agonists: ASC36, which targets the amylin receptor and is designed for once-monthly subcutaneous administration, and ASC37, a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Both components were discovered using Ascletis' proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. The combination strategy is intended to optimize weight loss and metabolic health by simultaneously activating multiple synergistic pathways to regulate appetite, glucose metabolism, and energy expenditure.
- Other names
- ASC36_37-Ascletis Bioscience-Amylin Receptor-GLP-1R-GIPR-GCGR-peptide (fixed-dose combination)-subcutaneous (SQ)-Obesity
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)AMY receptor (Calcitonin receptor (with ramps))GCGR (Glucagon receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on ASC36 + ASC37.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC36 + ASC37.